Mesenchymal Stem Cell Therapy for Ischemic Tissues.
Kar Wey YongJane Ru ChoiMehdi MohammadiAlim P MithaAmir Sanati-NezhadArindom SenPublished in: Stem cells international (2018)
Ischemic diseases such as myocardial infarction, ischemic stroke, and critical limb ischemia are immense public health challenges. Current pharmacotherapy and surgical approaches are insufficient to completely heal ischemic diseases and are associated with a considerable risk of adverse effects. Alternatively, human mesenchymal stem cells (hMSCs) have been shown to exhibit immunomodulation, angiogenesis, and paracrine secretion of bioactive factors that can attenuate inflammation and promote tissue regeneration, making them a promising cell source for ischemic disease therapy. This review summarizes the pathogenesis of ischemic diseases, discusses the potential therapeutic effects and mechanisms of hMSCs for these diseases, and provides an overview of challenges of using hMSCs clinically for treating ischemic diseases.
Keyphrases
- mesenchymal stem cells
- public health
- ischemia reperfusion injury
- cerebral ischemia
- endothelial cells
- oxidative stress
- stem cells
- bone marrow
- heart failure
- gene expression
- umbilical cord
- single cell
- atrial fibrillation
- left ventricular
- brain injury
- smoking cessation
- vascular endothelial growth factor
- wound healing
- blood brain barrier
- induced pluripotent stem cells
- chemotherapy induced